Voyager Therapeutics Inc
NASDAQ:VYGR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (0.4), the stock would be worth $-3.47 (182% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.5 | $4.23 |
0%
|
| 3-Year Average | 0.4 | $-3.47 |
-182%
|
| 5-Year Average | 0.4 | $-2.91 |
-169%
|
| Industry Average | 15.1 | $-116.81 |
-2 861%
|
| Country Average | 16.7 | $-129.23 |
-3 155%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Voyager Therapeutics Inc
NASDAQ:VYGR
|
249.8m USD | -0.5 | -2.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 715.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.1B USD | 21.9 | 86 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.7B USD | 23.1 | 24.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
168.6B USD | 18 | 19.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.5B USD | 28.5 | 28.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.8 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 11.6 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.8B EUR | 115.8 | 39.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 15.2 | 32.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -83.5 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Voyager Therapeutics Inc
Glance View
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.
